Eye Disease News and Research

RSS

Eye diseases are widespread around the globe. According to the World Health Organization, the most important three eye diseases or conditions that are a potential threat to the global population are diabetic retinopathy, glaucoma, and age-related macular degeneration. One more vital reason for visual harm is refractive errors. Some of the important reasons for vision loss or low vision are age, healthcare, gender, genetic problems and the prevalence of family history.

OXiGENE applies for voluntary delisting from SSE, continues to be listed on NASDAQ

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has applied for the voluntary delisting of OXiGENE common shares from the Stockholm Stock Exchange (SSE). The company will continue to be listed on the NASDAQ Global Markets exchange.

23 Apr 2010

Green tea catechins may protect against glaucoma and other common eye diseases: Scientists

Scientists have confirmed that the healthful substances found in green tea - renowned for their powerful antioxidant and disease-fighting properties - do penetrate into tissues of the eye. Their new report, the first documenting how the lens, retina, and other eye tissues absorb these substances, raises the possibility that green tea may protect against glaucoma and other common eye diseases.

22 Apr 2010

IP Advocate founder settles long-standing legal battle with UGARF

In a move that positions IP Advocate for its next chapter as a champion of research translation, founder Dr. Renee Kaswan today announced that she has settled her long-standing legal battle with the University of Georgia Research Foundation.

21 Apr 2010

A*STAR's BMRC and SIgN award grants for twelve research projects on infectious diseases and immunology

Twelve research projects on infectious diseases and immunology have been awarded grants by A*STAR's Biomedical Research Council (BMRC) and Singapore Immunology Network (SIgN) this year.

21 Apr 2010

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint>Europe, is due to report in the third quarter of 2010.

20 Apr 2010

Handheld SD-OCT device helps examine vitreoretinal interface in infants with SBS

Ophthalmologists examining infants for possible Shaken Baby Syndrome (SBS) found that a handheld Spectral Domain Optical Coherence Tomography (SD-OCT) device provided high-resolution images of the retina and the vitreoretinal interface in infants with SBS, reports a study in the current issue of Retina, The Journal of Retinal and Vitreous Diseases.

17 Apr 2010

Optovue founds "Eye-Give" non-profit foundation

Optovue, a pioneer in fourier/spectral-domain optical coherence tomography (OCT), has founded "Eye-Give," a non-profit foundation for the purposes of donating technology and funding to sight saving charities and organizations around the world.

13 Apr 2010

Implanting blue light-filtering IOLs during cataract surgery may help preserve retina health

Implanting blue light-filtering intraocular lenses during cataract surgery helps maintain visual function and may preserve the health of the retina, specifically in disease states such as age-related macular degeneration, according to a comprehensive review published in the May/June 2010 edition of Survey of Ophthalmology.

13 Apr 2010

HOLCOMB C3-R cures bobsledder of impending blindness, helps win gold at 2010 Winter Olympics

It was an amazing triumph of the will, when the U.S. Bobsled Team, led by captain Steve Holcomb, took home the first Gold in 62 years at the 2010 Winter Olympics in Vancouver. An amazing feat, yet only the tip of the iceberg, for 2 years prior Holcomb underwent a brand new procedure to cure his impending blindness.

7 Apr 2010

OXiGENE regains compliance for continued listing on NASDAQ Global Market

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has received a letter from NASDAQ Global Market exchange confirming that, with the appointment of Tamar Howson to the Company's audit committee, as detailed in the Company's Form 8-K filed on April 5, 2010, NASDAQ staff has determined that the Company complies with Listing Rule 5605(c)(2)

7 Apr 2010

Why is the genome project not yielding results faster?

As the genome projects reaches the 10 year landmark scientists are defending it. While the sequencing of the 3 billion letters in the human DNA took a long time the first draft of the human genome was presented ten years ago. Today it is possible to have your individual DNA mapped in a day and at the low cost of $5,000.

5 Apr 2010

BeaconEquity.com announces investment report featuring OXiGENE

BeaconEquity.com announces an investment report featuring OXiGENE Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

1 Apr 2010

Scientists use non-viral, synthetic nanoparticle carrier to restores vision

Take a look at this: Scientists from Buffalo, Cleveland, and Oklahoma City made a huge step toward making the blind see, and they did it by using a form of gene therapy that does not involve the use of modified viruses.

1 Apr 2010

Researcher explores the use of Chinese wolfberries to improve vision deficiencies

A Kansas State University researcher is exploring the use of Chinese wolfberries to improve vision deficiencies that are common for type-2 diabetics.

31 Mar 2010

READ 3 study for DME begins enrolling participants

A Phase II clinical trial for a promising treatment for diabetic eye disease has begun enrolling participants.

27 Mar 2010

New topical drug may help treat diabetic eye disease

Early-stage human clinical trials showed that a new topical drug was safe and had biological effects in a type of diabetic eye disease, and may offer researchers a new approach to prevent and treat diabetic macular edema.

26 Mar 2010

OXiGENE reports audited financial statements for fiscal year ended December 31, 2009

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that the audit report from its independent registered public accounting firm on its financial statements for the fiscal year ended December 31, 2009, included in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 16, 2010, contains an explanatory paragraph regarding the Company's ability to continue as a going concern.

19 Mar 2010

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD).

17 Mar 2010

OVD issue highlights prevalence of eye problems in general population

In the latest issue of Optometry & Vision Development (OVD), Dr. Dominick Maino, editor of OVD, notes that: "In 2010 there are 9 million people with lazy eye and 18 million individuals with eye-turns